Asparaginase Panel
Asparaginase Panel-994
PEG-asparaginase
PEG-L-asparaginase
Asparlas
Oncaspar
Erwinaze
L-Asparaginase
Rylaze
Used to monitor Asparaginase therapy for sufficient enzyme activity, to assess silent inactivation by patient sensitization (activity assay). To assess if a patient is producing antibodies against asparaginase (antibody assay).
Measurement of samples are made against a standard curve generated from E. coli L‐asparaginase with each run. Calculations for Erwinaze®, Oncaspar®, Asparlas, and Rylaze® were empirically derived and utilize a correction factor that has been correlated to the E. coli L‐asparaginase activity.
Immediately following collection, mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
- Transfer serum to a False bottom plasma/serum transport vial/tube (AHL), labelled as serum
Immediately following collection, mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
- Transfer serum to a false bottom plasma/serum transport vial/tube (AHL), labelled as serum
Indicate date and time of last injection on Granger Genetics Requistion
Frozen (preferred) - 30 days
Refrigerated - 3 days
Ambient - 1 day
Freeze/Thaw Cycles: 3
Gross hemolysis, lipemia or icterus
Spectrophotometry/absorbance-based enzyme‐coupled kinetic reaction
Traditional antigen-capture ELISA assay
None. Physician established therapeutic range.
83516 (antibody assay)
- 82657 x 4 (If the drug administered is not specified then results will be reported for Oncaspar, Erwinaze, Asparlas, and Rylaze)